-
Press ReleaseTest New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press ReleaseNovartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
-
Press ReleaseNovartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
-
Press ReleaseNovartis verzeichnet ein starkes zweites Quartal mit zweistelligem Umsatzwachstum und erhöhter Kerngewinnmarge; Prognose für das operative Kernergebnis im Geschäftsjahr 2025 angehoben
-
Press ReleaseNovartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
-
Press ReleaseNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
-
Press ReleaseNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten Quartal
-
Press ReleaseNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press ReleaseFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Press ReleaseNovartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024